Peptides having somatostatin activity

• US 4,190,648 A
• Filed: 03/13/1979
• Issued: 02/26/1980
• Est. Priority Date: 03/13/1979
• Status: Expired due to Term

• Current Assignee: Merck & Co., Inc.
• Original Assignee: Merck & Co., Inc.
• Inventors: Veber, Daniel F.
• Primary Examiner(s): Phillips, Delbert R.
• Assistant Examiner(s): Hazel, Blondel
• Application Number:
  US06/020,148
• Time in Patent Office: 350 Days
• Field of Search: 260/112.5 S, 260/112.5 R, 424/177
• US Class Current: 514/11.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/02 of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
• CPC Class Codes: C07K 14/6555 at least 1 amino acid in D-form
• CPC Class Codes: Y10S 930/16 Somatostatin; related peptides

Abstract

Peptides having the structural formula: ##STR1## wherein A is D-Thr, D-Val;

B is D-Phe, D-Tyr;

C is D-Phe, D-Tyr, O-Me-D-Tyr;

wherein the ring formed by the peptide backbone contains 26 atoms and pharmaceutically acceptable non-toxic acid addition salts thereof are prepared by the solid phase method. These peptides have the property of inhibiting release of insulin, inhibiting growth hormone release and inhibiting glucagon release in humans and animals without materially affecting gastric secretion. They have a longer duration of action than somatostatin.

Claims

1. Compounds of the formula:

##STR10## wherein A is D--Thr, D--Val;

B is D--Phe, D--Tyr;

C is D--Phe, D--Tyr, O--Me--D--Tyr;

wherein the ring formed by the peptide backbone contains 26 atoms and pharmaceutically acceptable non-toxic acid addition salts thereof.

2. The compounds according to claim 1 having the formula:

##STR11## and the pharmaceutically acceptable non-toxic acid addition salts thereof.

3. A composition comprising a therapeutically effective amount of the peptides having the structure:

##STR12## wherein A is D--Thr, D--Val,

B is D--Phe, D--Tyr,

C is D--Phe, D--Tyr, O--Me--D--Tyr

wherein the ring formed by the peptide backbone contains 26 atoms and pharmaceutically acceptable non-toxic acid addition salts thereof in a pharmaceutically acceptable excipient.